AstraZeneca PLC
ZEG
Company Profile
Business description
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
96,100
Stocks News & Analysis
stocks
ASX tech share upgraded following AI contract wins
Strong demand for AI infrastructure drives fair value lift.
stocks
5 star fully franked ASX dividend payer
Investors in cheap ASX share with a narrow moat enjoys a high yield, but there are risks investors should be aware of.
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,969.20 | 82.60 | 0.93% |
| CAC 40 | 7,983.96 | 51.91 | -0.65% |
| DAX 40 | 25,296.65 | 102.56 | -0.40% |
| Dow JONES (US) | 51,426.25 | 76.33 | 0.15% |
| FTSE 100 | 10,643.55 | 6.84 | 0.06% |
| HKSE | 24,613.27 | 89.70 | 0.37% |
| NASDAQ | 27,045.63 | 248.09 | 0.93% |
| Nikkei 225 | 66,753.72 | 1,272.45 | 1.94% |
| NZX 50 Index | 13,834.39 | 150.76 | 1.10% |
| S&P 500 | 7,711.10 | 40.26 | 0.52% |
| S&P/ASX 200 | 8,789.30 | 80.00 | 0.92% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |